C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
April 08 2024 - 8:00AM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science, presented a poster today at the American
Association for Cancer Research (AACR) Annual Meeting 2024
highlighting new preclinical data for CFT1946 across multiple
models of BRAF V600X mutant colorectal cancer (CRC) and non-small
cell lung cancer (NSCLC), additional BRAF inhibitor
(BRAFi)-resistant melanoma models, and an intracranial model of
BRAF V600E metastatic melanoma.
CFT1946 is an orally bioavailable BiDAC™ degrader that
selectively degrades the BRAF V600X mutant protein and prevents RAF
dimer-mediated resistance. While currently approved BRAF inhibitors
are also selective for BRAF V600X mutant proteins, their activity
is limited by primary or acquired resistance often mediated by
mechanisms that promote RAF dimerization. Further, in a significant
number of patients with BRAF V600X melanoma and NSCLC, the disease
metastasizes to the brain. BRAF inhibitors have limited brain
penetration, while CFT1946 demonstrates CNS activity in preclinical
models.
Key findings include:
- Promising activity of CFT1946 as a single agent in a broad
range of BRAF V600X preclinical models, including models of BRAFi
resistance.
- CFT1946 as a single agent and in combination with cetuximab
demonstrates superior activity to the standard of care combination,
BRAFi with cetuximab, in all CRC models tested to date, further
supporting the potential of a degrader advantage in this
setting.
- CFT1946 demonstrates superior prolongation of survival when
compared to encorafenib in an intracranial model of metastatic
melanoma.
Collectively, these data support the ongoing clinical evaluation
of CFT1946, which is the only BRAF V600X degrader in the clinic to
date. The CFT1946 Phase 1/2 trial continues to progress and data
from the Phase 1 monotherapy dose escalation portion of the trial
are expected to be presented in the second half of this year.
Details of the poster are as follows:
Title: CFT1946, a potent, selective BRAF
V600X mutant-specific degrader demonstrates superior activity as a
single agent to clinically approved BRAF inhibitors and standard of
care combinations in preclinical models of BRAF V600X melanoma,
CRC, NSCLC, and brain metastasisAbstract
Number: 1658Session Date and
Time: Monday April 8, 2024 9:00 AM - 12:30 PM
PTLocation: Poster Section 14Session
Title: Cell Signaling Components as Therapeutic
TargetsPresenter: Bridget Kreger, Ph.D.,
principal scientist, biology
The poster will be made available after the presentation under
the scientific presentations and publications page of the company’s
website at www.c4therapeutics.com.
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is progressing targeted oncology
programs through clinical studies and leveraging its
TORPEDO® platform to efficiently design and optimize
small-molecule medicines to address difficult-to-treat diseases.
C4T’s degrader medicines are designed to harness the body’s natural
protein recycling system to rapidly degrade disease-causing
proteins, offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. For more
information, please visit www.c4therapeutics.com.
About CFT1946CFT1946 is an orally bioavailable
BiDAC™ degrader designed to be potent and selective against BRAF
V600X mutant targets. In preclinical studies, CFT1946 is active in
vivo and in vitro in models with BRAF V600E driven disease and in
models resistant to BRAF inhibitors. CFT1946 is currently in a
Phase 1 dose escalation study in BRAF V600X mutant solid tumors
including colorectal cancer, non-small cell lung cancer and
melanoma. More information about this trial may be accessed at
www.clinicaltrials.gov (identifier: NCT05668585).
Forward-Looking StatementsThis press release
contains “forward-looking statements” of C4 Therapeutics, Inc.
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, but may not
be limited to, express or implied statements regarding our ability
to develop potential therapies for patients; the design and
potential efficacy of our therapeutic approaches; and the
predictive capability of our TORPEDO® platform in the development
of novel, selective, orally bioavailable BiDAC™ and MonoDAC™
degraders. Any forward-looking statements in this press release are
based on management’s current expectations and beliefs of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
For a discussion of the risks and uncertainties, and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in C4 Therapeutics’ most recent
Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as
filed with the Securities and Exchange Commission. All information
in this press release is as of the date of the release and C4
Therapeutics undertakes no duty to update this information unless
required by law.
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate
Communications & Patient
Advocacy LSpreen@c4therapeutics.com
C4 Therapeutics (NASDAQ:CCCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
C4 Therapeutics (NASDAQ:CCCC)
Historical Stock Chart
From Jul 2023 to Jul 2024